Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.34 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | PYGL | P06737 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.30 |
| ▸ | CNR2 | P34972 | 1/20 | 0.30 |
| ▸ | ECE1 | P42892 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27924591 | 1.00 | CA2 (0.45) | CA2ALDH1A1MAPTPTGS1SLC7A5 | |
| SCHEMBL7526611 | 1.00 | CA2 (0.45) | CA2ALDH1A1MAPTPTGS1SLC7A5 | |
| SCHEMBL3283921 | 0.82 | ALDH1A1 (0.46) | CA2ALDH1A1MAPTPTGS1LMNA | |
| SCHEMBL27626672 | 0.82 | ALDH1A1 (0.46) | CA2ALDH1A1MAPTPTGS1LMNA | |
| SCHEMBL8357912 | 0.80 | CA2 (0.43) | CA2ALDH1A1MAPTPTGS1SLC7A5 | |
| SCHEMBL883447 | 0.80 | CA2 (0.43) | CA2ALDH1A1MAPTPTGS1SLC7A5 | |
| SCHEMBL1236539 | 0.78 | CA2 (0.42) | CA2ALDH1A1MAPTPTGS1PYGL | |
| SCHEMBL8415890 | 0.78 | CA2 (0.42) | CA2ALDH1A1MAPTPTGS1PYGL | |
| SCHEMBL2515799 | 0.78 | CA2 (0.42) | CA2ALDH1A1MAPTPTGS1PYGL | |
| SCHEMBL20697781 | 0.76 | CA2 (0.41) | CA2ALDH1A1MAPTPTGS1PYGL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103396344-A | One-pot synthetic method for N-t-butyl-aminocarbonyl-3-methyl-L-valine | SUZHOU UUGENE BIOPHARMA CO LTD | 2013-11-20 | — | — | CN | claimed |
| US-8183408-B2 | Process for production of N-carbamoyl-tert-leucine | KANEKA CORPORATION (JP) | 2012-05-22 | — | — | US | claimed |
| US-20100256416-A1 | PROCESS FOR PRODUCTION OF N-CARBAMOYL-TERT-LEUCINE | KANEKA CORPORATION | 2010-10-07 | — | — | US | claimed |
| EP-2221294-A1 | PROCESS FOR PRODUCTION OF N-CARBAMOYL-TERT-LEUCINE | Kaneka Corporation (JP) | 2010-08-25 | — | — | EP | claimed |
| JP-7222593-A | — | — | None | — | — | JP | disclosed |
| CN-103396344-A | One-pot synthetic method for N-t-butyl-aminocarbonyl-3-methyl-L-valine | SUZHOU UUGENE BIOPHARMA CO LTD | 2013-11-20 | — | — | CN | disclosed |
| US-8183408-B2 | Process for production of N-carbamoyl-tert-leucine | KANEKA CORPORATION (JP) | 2012-05-22 | — | — | US | disclosed |
| US-8183408-B2 | Process for production of N-carbamoyl-tert-leucine | KANEKA CORPORATION (JP) | 2012-05-22 | — | — | US | disclosed |
| US-8183408-B2 | Process for production of N-carbamoyl-tert-leucine | KANEKA CORPORATION (JP) | 2012-05-22 | — | — | US | disclosed |
| US-20100256416-A1 | PROCESS FOR PRODUCTION OF N-CARBAMOYL-TERT-LEUCINE | KANEKA CORPORATION | 2010-10-07 | — | — | US | disclosed |
| US-20100256416-A1 | PROCESS FOR PRODUCTION OF N-CARBAMOYL-TERT-LEUCINE | KANEKA CORPORATION | 2010-10-07 | — | — | US | disclosed |
| EP-2221294-A1 | PROCESS FOR PRODUCTION OF N-CARBAMOYL-TERT-LEUCINE | Kaneka Corporation (JP) | 2010-08-25 | — | — | EP | disclosed |
| US-6800464-B2 | FOR PREPARATION OF D-AMINO ACIDS STARTING FROM 5'-SUBSTITUTED HYDANTOINS | DEGUSSA AG (DE) | 2004-10-05 | — | — | US | disclosed |
| EP-1373522-A2 | D-CARBAMOYLASE FROM ARTHROBACTER CRYSTALLOPOIETES DSM 20117 | Degussa AG (DE) | 2004-01-02 | — | — | EP | disclosed |
| US-20030143244-A1 | Arthrobacter D-carbamoylase and methods of preparing enantiomerically enriched D-amino acids | DEGUSSA AG (DE) | 2003-07-31 | — | — | US | disclosed |
| WO-2002077212-A2 | D-CARBAMOYLASE FROM ARTHROBACTER CRYSTALLOPOIETES DSM 20117 | DEGUSSA AG (DE) | 2002-10-03 | — | — | WO | disclosed |
| JP-H07222593-A | PRODUCTION OF N-CARBAMYL-L-TERT-LEUCINE | AJINOMOTO CO INC | 1995-08-22 | — | — | JP | disclosed |
| EP-0469739-B1 | Stationary phase for enantiomeric resolution in liquid chromatography | SHIMADZU CORP (JP) | 1994-06-15 | — | — | EP | disclosed |
| US-5149426-A | Stationary phase for enantiomeric resolution in liquid chromatography | SHIMADZU CORPORATION (JP) | 1992-09-22 | — | — | US | disclosed |
| EP-0469739-A1 | Stationary phase for enantiomeric resolution in liquid chromatography | SHIMADZU CORPORATION (JP) | 1992-02-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030143244-A1 | Arthrobacter D-carbamoylase and methods of preparing enantiomerically enriched D-amino acids | HDHD5, DDC, DAO | CA2 113/4885ALDH1A1 2078/4885MAPT 4057/4885 |
| US-20100256416-A1 | PROCESS FOR PRODUCTION OF N-CARBAMOYL-TERT-LEUCINE | TERT, BCAT1, BCAT2 | CA2 1234/4885ALDH1A1 3021/4885MAPT 771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.